A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC
Status:
Unknown status
Trial end date:
2020-11-09
Target enrollment:
Participant gender:
Summary
Evaluate the efficacy and safety of Anlotinib in combination with Docetaxel versus Docetaxel
in patients with advanced non-small lung cancer after failure of first-line Chemotherapy .
Phase:
Phase 2
Details
Lead Sponsor:
China Medical University, China
Collaborators:
Anshan Tumor Hospital Benxi Cental Hospital China Shenyang Chest Hospital General Hospital of Shenyang Military Region Liaohe Oil Field General Hospital Panjin Cental Hospital Panjin Central Hospital Panjin Liaohe Oilfield Gem Flower Hospital Shengjing Hospital Shenyang Chest Hospital The Affiliated Zhongshan Hospital of Dalian University The First People's Hospital of Jingzhou The People's Hospital of Liaoning Province The Second Affiliated Hospital of Dalian Medical University